Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


      © 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

api image Metamizol-Magnesium

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Metamizol Magnesium Manufacturers in India Suppliers Metamizol Magnesium Exporters Distributors Metamizol Magnesium api active pharmaceuticals ingredients Metamizol Magnesium manufacturers Side Effects bulk drugs raw material Metamizol Magnesium companies Side Effects Importers Metamizol Magnesium Metamizol Magnesium Exporters Metamizol Magnesium exporters FDA Metamizol Magnesium DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Metamizol Magnesium manufacturing pharmaceutical drugs pharmaceutical intermediates Metamizol Magnesium pharmaceutical chemicals pharmaceutical raw materials Metamizol Magnesium active pharmaceutical ingredients Metamizol Magnesium committee active pharmaceutical ingredients manufacturer Metamizol Magnesium Active Pharmaceutical Ingredients manufacturer Metamizol Magnesium exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Metamizol Magnesium, Metamizol Magnesium manufacturer India, Metamizol Magnesium product, Metamizol Magnesium products, Api preparation, Certificate of Analysis API manufacturer product, Metamizol Magnesium anti ulcer product, Certificate of Origin COA Metamizol Magnesium COS Metamizol Magnesium, pharmaceutical generic, pharmaceutical drug, medical, Metamizol Magnesium pharma healthcare, pharma patents, contract MSDS manufacturing Trader Metamizol Magnesium pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Metamizol Magnesium expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Metamizol Magnesium DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Metamizol Magnesium ingredients, api, HIV Metamizol Magnesium, tablets, capsules, syrup & protein Metamizol Magnesium powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Metamizol Magnesium gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Metamizol Magnesium WHO, UKMHRA Approval

   PRODUCT LIST
   Home
   API >>>
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 

Mesalamine img.




























 

 




 

 

HOME >> API >> API List 2 >> Metamizol Magnesium >> Drug Description

Metamizol Magnesium CAS No. 6150-97-6

DRUG DESCRIPTION
Metamizol Magnesium CAS No. 6150-97-6

Metamizol  is hydrolyzed in the gastrointestinal tract to the pharmacologically active metabolite 4-methyl-amino-antipyrine (4-MAA), which is transformed by both, oxidation to 4-formyl-amino-antipyrine (4-FAA) and demethylation to 4-amino-antipyrine (4-AA). 4-AA is acetylated to 4-acetyl-amino-antipyrine (4-AcAA). The aim of the present study was to investigate whether cimetidine will alter the pharmacokinetics of the metabolites of metamizol due to cimetidine-induced inhibition of the metabolic transformation of 4-MAA. The study was carried out in 12 patients with duodenal ulcer treated with cimetidine 1,000 mg daily over 20 days. A single oral dose of metamizol 1,500 mg was administered 2 days prior to commencement of cimetidine therapy to all patients. Two further doses of 750 and 1,500 mg of metamizol were given in a randomized order on days 8 and 13 during cimetidine treatment. Blood samples for determination of metamizol metabolites were drown over 48 hours post dose. Drug assays for metamizol metabolites and cimetidine were performed using HPLC methods. The patients were phenotyped for CYP2D6 and acetylation polymorphism. The results revealed that cimetidine interacted with 4-MAA by increasing the systemic availability, prolonging the elimination half-life and decreasing the systemic clearance of 4-MAA, whereas the renal clearances of 4-MAA remained unchanged. Consistent with cimetidine-induced changes in the oxidation of 4-MAA to 4-FAA, as well as in the demethylation of 4-MAA to 4-AA, were the decreased rates of production and the lower maximum concentrations of 4-FAA and 4-AA when metamizol was administered during cimetidine treatment (p < 0.05). No correlation was found between the decrease in the production rates of 4-FAA induced by cimetidine and the hydroxylation abilities of the patients, this suggesting that CYP2D6 is not involved in the metabolism of 4-MAA to 4-FAA. The acetylation of 4-AA to 4-AcAA was not affected by cimetidine. Cimetidine produced an increase not proportional to the dose in the systemic availability only of 4-MAA, whereas the kinetics of the other metabolites changed proportionally to the increasing dose of metamizol.

Metamizol Magnesium is a white, crystalline substance that is freely soluble in water. It differs chemically from the drugs of the thiouracil series primarily because it has a 5- instead of a 6-membered ring. Each tablet contains 5 or 10 mg (43.8 or 87.6 µmol) Metamizol Magnesium , an orally administered antithyroid drug.

Each tablet also contains lactose monohydrate, magnesium stearate, starch (corn), pregelatinized starch and talc.

Antispasmodic drugs have been used to treat stomach cramps. Traditionally, they were used to treat stomach ulcers, but for this purpose they have largely been replaced by the acid inhibiting compoundsa, the H-2 receptor blockers such as cimetidine and ranitidine and the proton pump inhibtors such as omeprazole, lansoprazole and rabetazole.

Most of the drugs used for this purpose as "anti-cholinergics", since they counteract the effects of the neurohormone acetylcholine. Some of these drugs are derived from the plant belladonna, also known as Deadly Nightshade. There is also a group of drugs with similar activity, but not taken from plant sources. The anticholingergics decrease both the movements of the stomach and intestine, and also the secretions of stomach acid and digestive enzymes. They may be used for other purposes including treatment of Parkinson's Disease, and bladder urgency. Because these drugs inhibit secretions, they cause dry mouth and dry eyes because of reduced salivation and tearing. Dicyclomine is an antispasmodic with very lettle effect on secretions. It is used to treat irritable bowel syndrome.

Information Associated with Product:
DRUG DESCRIPTION >>
DOSAGE
SIDE EFFECTS
PRECAUTIONS
INTERACTION
CONSUMER INFORMATION
 
 
PDF DOWNLOAD WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo

Metamizol Magnesium

Api Manufacturer,Export,Supplies,Manufacturing

Gabapentin

Gemcitabine Hcl

Glimepiride

Granisetron Hcl

Ibandronate Sodium

Imatinib Mesylate

Irbesartan

Irinotecan Hcl

Isradipine

Lamotrigine

Lercanidipine

Letrozole

Losartan Potassium

Loteprednol Etabonate

Magnesium Valproate

Meloxicam

Memantine Hcl

Mesalazine

Metamizol Magnesium

Metaxalone

Metformin Hcl

Metoprolol Tartrate

Mifepristone

Mirtazapine

Modafinil

Mometasone Furoate

Naltrexone Hcl

Netaglinide

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap
 

taj group logo
© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited  products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.